Log in to search using one of your social media accounts:

 

PML Reported in Patient Receiving Ocrelizumab PML Reported in Patient Receiving Ocrelizumab
But the case could be attributable to'carryover'from the patient's previous treatment with natalizumab, the company said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Genentech Reports PML Case with Ocrelizumab
(MedPage Today) -- Occurred in patient transitioning from natalizumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2017 Category: Primary Care Source Type: news

Enhanced Atypical Lymphocytes in Natalizumab - Treated MS
Enhanced fraction of atypical lymphocytes, especially binucleated and plasmacytoid lymphocytes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 24, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Neurology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

March's top stories: Perrigo's $2.85bn sale, Cancer Research UK's Precision Panc project
Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-techn … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 2, 2017 Category: Pharmaceuticals Source Type: news

Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 27, 2017 Category: Pharmaceuticals Source Type: news

Perrigo to sell Tysabri drug royalty to RPI for $2.85bn
Ireland-based Perrigo has signed an agreement to sell its right to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma ’s (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 1, 2017 Category: Pharmaceuticals Source Type: news

Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details. Get the full story at our sister site, Drug Delivery Business News. T...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Neurological Pharmaceuticals Wall Street Beat Biogen Source Type: news

Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera. Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 2, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera. Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk
In multiple sclerosis (MS) patients treated with natalizumab, the risk of developing progressive multifocal leukoencephalopathy (PML) does not appear to be associated with high blood levels of the drug, preliminary research from the Netherlands suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Perrigo to review options for Multiple Sclerosis drug Tysabri
(Reuters) - Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri. (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Alemtuzumab Comparison Data Show Some Surprises Alemtuzumab Comparison Data Show Some Surprises
New observational propensity-matched data on head-to-head comparisons of alemtuzumab with beta-interferon, fingolimod, and natalizumab show some unexpected findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

MRI May Help Differentiate Asymptomatic PML From New MS Lesions MRI May Help Differentiate Asymptomatic PML From New MS Lesions
MRI criteria can be used to differentiate asymptomatic progressive multifocal leukoencephalopathy (PML) from new multiple sclerosis (MS) lesions during natalizumab pharmacovigilance, researchers from the Netherlands report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 21, 2016 Category: Radiology Tags: Neurology & Neurosurgery News Source Type: news

Registry Data: Lemtrada More Effective than Competing MS Tx
(MedPage Today) -- Better than fingolimod or interferon; comparable to natalizumab (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 17, 2016 Category: Journals (General) Source Type: news

ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)
(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 16, 2016 Category: Consumer Health News Source Type: news

Extended Interval Dosing of Natalizumab in Multiple Sclerosis Extended Interval Dosing of Natalizumab in Multiple Sclerosis
Could risk of PML with natalizumab be reduced in MS patients, without compromising efficacy, by extending the interval between doses?Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Tysabri (Natalizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 1, 2016 Category: Drugs & Pharmacology Source Type: news

Relapses Rebound in Patients With MS Stopping FingolimodRelapses Rebound in Patients With MS Stopping Fingolimod
As seen with natalizumab, a new study shows patients may experience rebound in relapses after stopping fingolimod. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Natalizumab Misses Endpoint in Secondary Progressive MSNatalizumab Misses Endpoint in Secondary Progressive MS
In the ASCEND trial, treatment did not delay disease progression, the primary endpoint, although there was a benefit on upper-extremity function. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 26, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab outperforms fingolimod after natalizumab switch
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests. (Source: MedWire News)
Source: MedWire News - April 26, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news

Tysabri No Help in SPMS
(MedPage Today) -- Drug didnt reduce disability progression but may benefit upper limb function (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 22, 2016 Category: Primary Care Source Type: news

Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study included patients infected with JC virus, which is present in approximately 50% of the general population. While the virus generally causes no problems under normal circumstances, it can cause progressive multifocal leukoencephalopathy (PML), a serious demyelinating disease of the brain, in patients with immune deficiencies due to disease or immunosuppressant drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news

Rituximab bests fingolimod in MS patients switching from natalizumab
For patients with relapsing-remitting multiple sclerosis (RRMS) switching to other therapies due to positive JC virus serology, treatment with rituximab resulted in a lower rate of clinical relapse... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 4, 2016 Category: Neurology Source Type: news

What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Could MS Drug Have a Role in Acute Stroke?Could MS Drug Have a Role in Acute Stroke?
A new study looking at natalizumab to treat stroke showed no effect on the primary endpoint of infarct volume growth, but there was a hint of some clinical benefit. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

No Benefit for Natalizumab Within 9 Hours of Stroke (CME/CE)
(MedPage Today) -- Early data found no benefit on MRI or NIHSS scores for potent monoclonal antibody (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 19, 2016 Category: Cardiology Source Type: news

New EMA Advice for PML Prevention With Tysabri in MSNew EMA Advice for PML Prevention With Tysabri in MS
The European Medicines Agency has released new recommendations on PML prevention with natalizumab in multiple sclerosis. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Natalizumab Ups JCV Seroconversion, Antibody Index in MSNatalizumab Ups JCV Seroconversion, Antibody Index in MS
New data shed some light on the mechanism behind the PML risk with natalizumab and emphasize the need for regular JC virus testing, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 30, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Stratification of Natalizumab-Associated PML RiskStratification of Natalizumab-Associated PML Risk
This consensus paper presents a practical algorithm which can be used to stratify patients with MS according to their risk of developing PML during treatment with natalizumab. Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2016 Category: Pathology Tags: Neurology & Neurosurgery Journal Article Source Type: news

MS Drug Tied to Higher Risk for Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease (Source: WebMD Health)
Source: WebMD Health - January 27, 2016 Category: Consumer Health News Source Type: news

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease Source: HealthDay Related MedlinePlus Page: Multiple Sclerosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 27, 2016 Category: Consumer Health News Source Type: news

More Tysabri Patients Turn Positive for JC Virus Antibodies (CME/CE)
(MedPage Today) -- Seroconversion rates on treatment much higher than expected (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 27, 2016 Category: Neurology Source Type: news

PML With Natalizumab Despite Recent Negative JCV Test ResultPML With Natalizumab Despite Recent Negative JCV Test Result
Because the first sign of PML was seen in new MRI findings, this case report underlines the value of surveillance imaging in patients receiving natalizumab, researchers say. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Natalizumab in the Pediatric MS PopulationNatalizumab in the Pediatric MS Population
Is natalizumab safe and effective for use in pediatric MS patients who have not responded to other therapies? BMC Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

No Conclusions About MS Drug Superiority (CME/CE)
(MedPage Today) -- Two cohort studies give opposing views of natalizumab versus fingolimod efficacy (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 9, 2015 Category: Neurology Source Type: news

New Data Show Longer Tysabri Dosing Interval in MS Is Feasible (CME/CE)
(MedPage Today) -- But available data remain underpowered to confirm PML risk reduction (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 7, 2015 Category: Neurology Source Type: news

Conversion to JCV Positivity Common With Natalizumab in MS Conversion to JCV Positivity Common With Natalizumab in MS
A study including longitudinal analysis of patients with MS treated with natalizumab shows no link between duration of treatment and conversion to JCV antibody positivity or PML. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Tysabri May be Tx Option in Kids With MS (CME/CE)
(MedPage Today) -- Italian registry study suggests treatment is safe and effective (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - September 30, 2015 Category: Pediatrics Source Type: news

Disease modifying drugs
A Cochrane review of disease modifying drugs for relapsing MS found that the best at reducing relapse in the first two years of treatment were alemtuzumab, mitoxantrone, natalizumab and fingolimod. The best at reducing the build up of disability in the same period were mitoxantrone, alemtuzumab, and natalizumab. The review criticises the lack of long-term evidence for efficacy and side effects. MS News Today Disease modifying drugs for relapsing MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 21, 2015 Category: Neurology Source Type: news

Switching From Natalizumab to Fingolimod in RRMSSwitching From Natalizumab to Fingolimod in RRMS
This study aims to improve our understanding of drug-induced immune changes and potential disease exacerbation during switch-over from natalizumab to fingolimod in treatment of RRMS. BMC Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

MS drugs during pregnancy
A review of different studies looking at the effects of Betaferon, teriflunomide and natalizumab on women with MS who become pregnant. Although the numbers are relatively small, Results suggest that there was no increase in spontaneous abortions or birth abnormalities. MS Research Australia Pregnancy - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - August 10, 2015 Category: Neurology Source Type: news

Tysabri and cognition
A small Italian study found that after three years, people with MS taking natalizumab (Tysabri) did better on tests of cognition as well as showing reduced relapse rates and stable EDSS. MS News Today Cognition and cognitive symptoms - A to Z of MS Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 12, 2015 Category: Neurology Source Type: news

Natalizumab SC Similar to IV Every 4 Weeks for MSNatalizumab SC Similar to IV Every 4 Weeks for MS
A randomized comparison finds subcutaneous and intravenous administration of natalizumab similar when given every 4 weeks, but the company, Biogen, has decided not to pursue the product after all. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 22, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

What's the Optimal Washout After Natalizumab in MS? What's the Optimal Washout After Natalizumab in MS?
A new study suggests that shorter washout periods may be better than longer ones, and even that no washout may be needed at all. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 15, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Timing the switch from Tysabri to Gilenya
A study has been published showing that a shorter washout time when changing from treatment with natalizumab (Tysabri) to fingolimod (Gilenya) reduces the risk of relapse. MS Research Australia Natalizumab (Tysabri) - A to Z of MS Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 8, 2015 Category: Neurology Source Type: news

No Surprises with Tysabri-Tecfidera Switch
(MedPage Today) -- Discontinuation rates for both agents were in line with those seen in clinical trials (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 2, 2015 Category: Journals (General) Source Type: news

'We expected our daughter's MS but it still felt like a bombshell'
Childhood multiple sclerosis often goes undetected but Lucy Wood's early diagnosis at the age of five has been crucial in reducing her disability over time (Source: The Telegraph : Health Advice)
Source: The Telegraph : Health Advice - May 11, 2015 Category: Consumer Health News Tags: Professor Susan Kirk myelin University of Manchester paediatric MS Multiple sclerosis Tysabri Dr Cheryl Hemingway Source Type: news

Tysabri Review Launched in EuropeTysabri Review Launched in Europe
New scientific data have prompted experts to see whether changes are warranted for managing risks for progressive multifocal leukoencephalopathy in patients taking natalizumab. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 8, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Gilenya fails in progressive MS / Tysabri injections
A round up of presentations from AAN includes a study that found fingolimod (Gilenya) didn't slow progressive MS and research that shows injections of natalizumab (Tysabri) were as effective as infusions. Presented at the American Academy of Neurology (AAN) meeting. MedPage Today Fingolimod (Gilenya) - A to Z of MS Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 23, 2015 Category: Neurology Source Type: news